| Registry | NCT02688465, acronym POMPRENELLE |
|---|---|
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional; na, single group, masking: none, treatment |
| Enrollment | 15 (Actual) |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild (Network) |
| Conditions | Parkinson's Disease |
| Interventions | Apomorphine (Drug) |
| Dates | start 2016-09-05, primary completion 2017-01-01, completion 2017-07-01, first posted 2016-02-23, last updated 2018-03-26 |
| Locations | 1 site in France |
Related Papers Related Patents Related Grants Related Experts
All trials for Parkinson's Disease All trials of Apomorphine
Parkinson's disease is not only a pathology of movements. There are many non-motor symptoms that complicate and impair patients' quality of life. Among those disorders are sleep disorders.
Insomnia is the most frequent symptom. Most patients report 2-5 awakenings per night and long periods of awakening which occupy 30 to 40% of their night.
Apomorphine is a dopamine agonist that may be administered with a pump . The objective of the study is to assess changes in the quality of sleep in Parkinson's disease patients treated with an apomorphine pump.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Apomorphine pump | Experimental | Drug: Apomorphine |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Parkinson's disease patients for whom a treatment with an apomorphine pump is indicated Exclusion Criteria: * atypical parkinsonian syndrome * cognitive impairment * pregnancy * breast feeding * patient under a legal protection procedure * patient denying to participate to the study * lack of affiliation to a social security system
| Facility | City | Country | Status |
|---|---|---|---|
| Fondation ophtalmique Adolphe de Rothschild | Paris | France |